GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Sutro Biopharma Inc.
Sutro Biopharma is a biotech company with a unique platform for producing antibody-based drugs. Its stock price is a bet on the success of its technology. The chart reflects both the progress of its own developments and partnerships with major pharmaceutical companies.
Share prices of companies in the market segment - Oncology immuno-therapy
Sutro Biopharma has developed a unique platform for cell-free protein synthesis, enabling the rapid design and production of a new generation of complex anticancer drugs, such as antibody-drug conjugates. We've classified it in the "Oncology Immunotherapy" segment. The chart below shows the overall dynamics in this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
Sutro Biopharma is a biotech company using its platform to develop next-generation cancer treatments, including antibody-drug conjugates. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Sutro compares to it.
Change in the price of a company, segment, and market as a whole per day
STRO - Daily change in the company's share price Sutro Biopharma Inc.
For Sutro Biopharma, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter for risk assessment formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
For Sutro Biopharma, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in the risk assessment formulas at GURU.Markets.
Daily change in the price of a broad market stock, index - GURU.Markets
Sutro Biopharma is developing a new generation of immuno-oncology drugs to fight cancer. This is at the cutting edge of science, where every news about clinical trials can cause a storm. Sutro's share price fluctuations reflect the high hopes and risks of biotech, adding a powerful innovative charge to the overall market pulse, visible on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Sutro Biopharma Inc.
For Sutro Biopharma, Inc., year-over-year performance is a story about its unique platform for creating antibody-drug conjugates (ADCs). Its 12-month market cap is entirely dependent on clinical trial data. Partnerships with giants like Bristol Myers Squibb confirm the potential of its technology for creating next-generation cancer drugs.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Sutro Biopharma, Inc. is a clinical-stage biotechnology company with a unique platform for developing a new class of cancer drugs. Its stock price reflects both the potential of its scientific platform and the risks associated with clinical trials, which is typical for the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sutro Biopharma is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Sutro Biopharma Inc.
Sutro Biopharma is an oncology company with a unique platform for producing antibody-drug conjugates (ADCs). Its monthly performance is driven by news from its clinical programs and partners. Positive trial data is generating significant investor interest.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Sutro Biopharma is developing a new generation of cancer treatments, including antibody-drug conjugates, using its unique protein synthesis platform. The company's value depends on the success of its clinical trials. The oncology sector's performance reflects investor interest in innovative approaches, which provides a backdrop for the valuation of Sutro's technology.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sutro Biopharma is developing a new generation of immuno-oncology drugs. Like many biotech companies, its shares follow the clinical trials calendar. Its monthly price action is largely independent of overall market sentiment, reflecting investor confidence in the company's breakthrough technologies, as the chart clearly demonstrates.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Sutro Biopharma Inc.
Sutro Biopharma, a biotech company developing innovative cancer treatments, exhibits high volatility. Weekly stock performance is driven by news about clinical trials and partnerships, reflecting the risks and potential of its unique platform.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Sutro Biopharma is developing a new generation of cancer treatments using its precision protein synthesis platform. This chart compares its data-driven performance with the immuno-oncology sector and assesses investor confidence in the superiority of its technology.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Sutro Biopharma is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that STRO's performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
STRO - Market capitalization of the company Sutro Biopharma Inc.
Sutro Biopharma's stock chart is a financial map of precision engineering in oncology. The company's market cap reflects its confidence in its platform for creating complex drugs, such as antibody-drug conjugates (ADCs). Its performance is a barometer of progress in clinical trials and the ability of its technology to create more effective cancer treatments.
STRO - Share of the company's market capitalization Sutro Biopharma Inc. within the market segment - Oncology immuno-therapy
Sutro Biopharma's market share in immuno-oncology reflects its breakthrough cell-free protein synthesis technology. Its market share is based on the potential of this platform for the rapid development and production of innovative cancer drugs, such as antibody-drug conjugates (ADCs).
Market capitalization of the market segment - Oncology immuno-therapy
Sutro Biopharma is developing a new generation of oncology drugs using its protein synthesis platform. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect hopes that new technologies will make drug development more precise and faster.
Market capitalization of all companies included in a broad market index - GURU.Markets
Sutro Biopharma has developed a unique platform for creating a new generation of antibody-based drugs for cancer treatment. Its market capitalization is a bet on this technology. The chart below shows the economic weight of biotech companies with innovative manufacturing platforms.
Book value capitalization of the company, segment and market as a whole
STRO - Book value capitalization of the company Sutro Biopharma Inc.
Sutro Biopharma's book value is determined by its unique antibody production platform and capital. The chart below shows the material base for its scientific development. Its dynamics reflect investments in R&D and payments received from major pharmaceutical partners.
STRO - Share of the company's book capitalization Sutro Biopharma Inc. within the market segment - Oncology immuno-therapy
Sutro Biopharma is a biotech company with a unique protein production platform. Unlike many, it has its own manufacturing facilities. The asset share chart shows how its physical footprint is a key advantage, giving it control over its complex production process.
Market segment balance sheet capitalization - Oncology immuno-therapy
Sutro Biopharma is a biotech company. Unlike many "light" startups, it has its own unique platform for cell-free protein synthesis, making its R&D more capital-intensive. The graph will show whether this model (science + unique production) is the norm for the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
Sutro Biopharma's balance sheet is a unique platform for cell-free protein synthesis, enabling the rapid creation and production of complex oncology drugs, such as antibody-drug conjugates. The company's assets represent the capital invested in this breakthrough manufacturing technology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Sutro Biopharma Inc.
Sutro Biopharma is a biotech company with a unique protein production platform that enables the creation of more precise oncology drugs. Its market capitalization is the valuation of this technology platform. The chart shows how investors value its partnerships and pipeline built on this innovative technology.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Sutro Biopharma is a biotech company with a unique protein production platform that enables the creation of more effective cancer drugs. Its value lies in this technology. The chart shows the enormous premium the market pays for its innovative scientific platform.
Market to book capitalization ratio for the market as a whole
Sutro Biopharma is a biotech company with a unique platform for producing more precise and effective cancer drugs. The chart shows how the market values its cutting-edge technology. The company's market capitalization reflects investors' bet that its platform will be able to create blockbuster drugs, a typical feature of innovative biotech.
Debts of the company, segment and market as a whole
STRO - Company debts Sutro Biopharma Inc.
Sutro Biopharma is a clinical-stage biopharmaceutical company with a unique platform for producing oncology drugs. Debt is a means of funding expensive clinical trials and scaling its complex manufacturing process, as this chart illustrates.
Market segment debts - Oncology immuno-therapy
Sutro Biopharma is a biopharmaceutical company that uses its platform to produce complex protein drugs, such as antibody-drug conjugates, for the treatment of cancer. The chart illustrates the financial norms for the biotech sector, where companies raise vast amounts of capital to finance their unique manufacturing technologies and conduct expensive clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Sutro Biopharma Inc.
Sutro Biopharma is developing a new generation of oncology drugs, including antibody-drug conjugates (ADCs). This is a complex and expensive technology. This chart shows the proportion of debt funding for its breakthrough research. This is a key indicator of the financial risk for a biotech company on the path to developing an effective treatment.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
The development of complex antibodies for cancer treatment, like Sutro Biopharma's, is based on a unique cell-free synthesis technology. This chart illustrates how the biotech sector funds its innovations. It allows one to appreciate the capital intensity of this cutting-edge platform and how Sutro's financial model differs from other companies working in the field of immuno-oncology.
Debt to book value of all companies in the market
Sutro Biopharma is developing a new generation of cancer drugs using a unique protein synthesis platform. This is a capital-intensive biotech process. The chart shows how their debt load, necessary to fund breakthrough research, compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Sutro Biopharma Inc.
This metric for Sutro Biopharma, a biopharmaceutical company with an innovative cancer drug discovery platform, reflects its belief in its science. The company's value is determined not by current profits, but by the potential of its unique technology to develop more effective cancer treatments.
P/E of the market segment - Oncology immuno-therapy
This indicator represents the average valuation for the biotech sector in which Sutro Biopharma operates. It reflects the overall level of investor optimism regarding immuno-oncology. The chart provides a benchmark for understanding how the market values Sutro's unique platform relative to the broader industry.
P/E of the market as a whole
Sutro Biopharma has developed a unique protein production platform that enables the creation of more precise and effective cancer treatments, specifically antibody-drug conjugates. This graph highlights interest in oncology. It helps understand whether the market sees a real competitive advantage in Sutro's technology and how it views the potential of its own and partner programs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Sutro Biopharma Inc.
Sutro Biopharma is a biotechnology company developing next-generation cancer drugs, specifically antibody-drug conjugates (ADCs), using its unique protein synthesis platform. The company's future depends on the success of its clinical programs. This chart reflects investor expectations regarding its innovative technology and the potential of its drugs.
%20P%2FE%20Sutro%20Biopharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Sutro-Biopharma-Inc.&v=1772588509676 "Chart of the company's future (projected) P/E Sutro Biopharma Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Sutro Biopharma has developed a proprietary platform for cell-free protein synthesis, enabling the rapid creation and production of complex cancer treatments, such as antibody-drug conjugates. This chart reflects expectations for the biotech sector, helping to assess the market's appreciation for this unique manufacturing technology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772588509706 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Sutro Biopharma is a biotech company developing a new generation of cancer immunotherapy drugs, specifically antibody-drug conjugates (ADCs). Their platform enables the precise creation of complex molecules. This graph of overall expectations demonstrates the market's willingness to fund advanced oncology. Investor optimism is essential to support such complex and capital-intensive developments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772588509863 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Sutro Biopharma Inc.
Sutro Biopharma is a biotech company developing next-generation cancer drugs, specifically antibody-drug conjugates (ADCs). This chart shows the cost of innovative research. Profits depend on the success of clinical trials and partnerships with major pharmaceutical companies to bring its drugs to market.
Profit of companies in the market segment - Oncology immuno-therapy
Nine Energy Service provides oilfield services, specializing in well completion technologies. Its profitability, like KLX's, is directly dependent on drilling activity and oil prices. This chart clearly illustrates the highly cyclical and volatile nature of the oilfield services sector, whose financial results closely follow the investment cycles of the upstream industry.
Overall market profit
Sutro Biopharma is developing a new generation of oncology drugs, including antibody-drug conjugates (ADCs) and cytokines. The company's unique platform enables the precise creation of complex molecules. Its success depends on the results of clinical trials that can confirm the superiority of its approach in cancer treatment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Sutro Biopharma Inc.
Sutro Biopharma is a biotech company developing a new generation of oncology drugs, specifically antibody-drug conjugates (ADCs). Its revenue forecast depends on the success of clinical trials. This chart shows analyst expectations for its innovative protein production platform and the potential of its drugs.
%20profit%20of%20the%20company%20Sutro%20Biopharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Sutro-Biopharma-Inc.&v=1772588510208 "Graph of future (projected) profit of the company Sutro Biopharma Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Sutro Biopharma has developed a unique platform for cell-free protein synthesis, enabling the rapid creation and production of complex oncology drugs, such as antibody-drug conjugates. This chart shows profitability forecasts for the biotech sector. It reflects the potential of breakthrough manufacturing technologies to accelerate the development of new drugs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772588510258 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Sutro Biopharma is developing a new generation of immuno-oncology drugs. Its future depends on success in clinical trials. The overall economic forecast, illustrated by this chart, is critical for assessing the investment climate. It influences the willingness of investors and large pharmaceutical companies to finance breakthrough but risky technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772588510300 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Sutro Biopharma Inc.
Sutro Biopharma is a biotech company with a unique cell-free protein synthesis platform that enables the rapid creation and production of complex drugs, such as antibody-drug conjugates (ADCs) for cancer treatment. The chart reflects the company's strong valuation of its innovative technology, not its current revenue.
P/S market segment - Oncology immuno-therapy
Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company developing next-generation cancer treatments, including antibody-drug conjugates (ADCs) and cytokines. This chart shows the average valuation in the sector, providing insight into the market's perception of the revenue potential of Sutro's innovative platform.
P/S of the market as a whole
Sutro Biopharma is developing a new generation of cancer treatments using its platform for precise protein drug synthesis. The company focuses on antibody-drug conjugates. This chart, showing average valuations, clearly demonstrates the premium investors place on the company's revenue, given its breakthrough technology platform in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Sutro Biopharma Inc.
Sutro Biopharma has developed a platform for the precise design and production of complex protein drugs, primarily for cancer immunotherapy. This chart illustrates how investors assess the future potential of its technology. This assessment is based on expectations for successful clinical trials of its own candidates and partner programs.
%20P%2FS%20Sutro%20Biopharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Sutro-Biopharma-Inc.&v=1772588510372 "The graph of the company's future (projected) P/S Sutro Biopharma Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Sutro Biopharma has developed the XpressCF+ platform for the high-precision production of cytokines and antibodies. This enables the creation of innovative immuno-oncology drugs. The graph shows the premium investors are willing to pay for Sutro's future sales, reflecting the potential of its unique technology to create more effective cancer drugs.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772588510399 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Investor optimism about future revenues depends on new technologies in drug development. Sutro Biopharma, with its platform for precisely designing antibody-drug conjugates (ADCs), aims to make chemotherapy more targeted and less toxic. Their scientific successes support the belief that new engineering approaches will lead to breakthroughs in cancer treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772588510525 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Sutro Biopharma Inc.
Sutro Biopharma is a clinical-stage biopharmaceutical company leveraging its unique platform to develop next-generation cancer treatments. Its revenue at this stage is generated not from sales, but from upfront and milestone payments from major pharmaceutical co-development partners.
Sales of companies in the market segment - Oncology immuno-therapy
Sutro Biopharma has developed a unique protein manufacturing platform that enables the creation of more precise and potent cancer treatments, including antibody-drug conjugates. This chart represents overall revenue in the immuno-oncology sector. It illustrates Sutro's advanced drug discovery technologies, where it strives to improve the efficacy and safety of treatments.
Overall market sales
Sutro Biopharma is a clinical-stage biopharmaceutical company developing a new generation of cancer treatments, including antibody-drug conjugates. Its platform enables the creation of more precise and effective drugs. Success depends on clinical data. This overall economic climate impacts the availability of capital for cutting-edge oncology research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Sutro Biopharma Inc.
Sutro Biopharma is developing a new generation of oncology drugs, including antibody-drug conjugates (ADCs), using its cell-free protein synthesis platform. The future depends on the success of clinical trials. The chart shows analysts' speculative forecasts, betting on a breakthrough in targeted cancer therapy.
%20sales%20of%20the%20company%20Sutro%20Biopharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Sutro-Biopharma-Inc.&v=1772588510630 "Schedule of future (projected) sales of the company Sutro Biopharma Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Sutro Biopharma has developed a unique platform for cell-free protein production, enabling the rapid creation and optimization of complex cancer treatments such as antibody-drug conjugates (ADCs). This graph displays projected revenues for the entire immuno-oncology sector, providing insight into overall expectations for the market for innovative drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772588510651 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Sutro Biopharma is a clinical-stage biopharmaceutical company developing a new generation of oncology therapeutics (antibody-drug conjugates). Its value depends on the success of its scientific platform. This general economic activity schedule influences the availability of capital for the biotech sector, which is necessary to finance expensive and time-consuming research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772588510668 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Sutro Biopharma Inc.
Sutro Biopharma is developing a new generation of cancer drugs using its unique protein synthesis platform. This indicator reflects the financial impact of its cutting-edge research. It demonstrates the investment in clinical trials required to commercialize its innovative approach to oncology drug development.
Market segment marginality - Oncology immuno-therapy
Sutro Biopharma is a biopharmaceutical company developing a new generation of oncology therapeutics using its cell-free protein synthesis platform. This indicator reflects its operational structure and the level of investment in its unique scientific platform compared to other immuno-oncology companies.
Market marginality as a whole
Sutro Biopharma is a clinical-stage biopharmaceutical company developing a new generation of cancer treatments, including antibody-drug conjugates (ADCs). Their unique platform enables precise protein modification. Their success depends on clinical trials. This overall profitability profile is impacted by the overall investment climate in oncology.
Employees in the company, segment and market as a whole
Number of employees in the company Sutro Biopharma Inc.
Sutro Biopharma is a biotech company with a unique protein production platform enabling the creation of innovative oncology drugs. This chart shows the size of its research and production team. Growth here reflects both progress in clinical trials and investments in its own manufacturing facilities.
Share of the company's employees Sutro Biopharma Inc. within the market segment - Oncology immuno-therapy
Sutro Biopharma has developed a unique platform for producing complex proteins, such as antibody-drug conjugates (ADCs). This graph shows the concentration of elite scientists in the field of protein engineering. The Sutro team is at the forefront of creating a new generation of precision cancer drugs.
Number of employees in the market segment - Oncology immuno-therapy
Sutro Biopharma, Inc. is a biotechnology company using its cell-free protein synthesis platform to develop next-generation cancer drugs, specifically antibody-drug conjugates. This chart shows overall employment in the immunotherapy sector, illustrating the company's cutting-edge scientific approach to creating more precise and effective treatments.
Number of employees in the market as a whole
Sutro Biopharma has developed a unique platform for cell-free protein production, enabling the rapid creation of complex cancer treatments, particularly antibody-drug conjugates. This graph illustrates the labor market, where biotech innovators like Sutro are creating demand for exceptional specialists in biochemistry and synthetic biology.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Sutro Biopharma Inc. (STRO)
Sutro Biopharma, Inc. is a biopharmaceutical company developing a new generation of oncology drugs using its protein synthesis platform. This chart is a prime example of biotech. The very high market capitalization per employee demonstrates that investors are investing in the potential of a unique scientific platform rather than current operating metrics.
%20of%20the%20company%20Sutro%20Biopharma%20Inc.%20(STRO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Sutro-Biopharma-Inc.-STRO&v=1772588510998 "Chart of market capitalization per employee (in thousands of dollars) of the company Sutro Biopharma Inc. (STRO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Sutro Biopharma has developed a proprietary protein production platform that enables the creation of innovative cancer treatments. The company's entire value lies in its unique technology. This metric demonstrates the enormous premium the market places on their scientific breakthroughs. This high metric reflects investors' belief that their platform will transform oncology.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772588511071 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company with a unique platform for developing more effective cancer drugs. Its valuation is based on the potential of this technology. This metric reflects the high valuation of breakthrough scientific approaches that could lead to the development of a new generation of oncology drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772588511168 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Sutro Biopharma Inc. (STRO)
Sutro Biopharma (STRO) is a clinical-stage biotech R&D company. They use their unique platform to develop complex oncology drugs (ADCs, cytokines). This is pure science. This metric demonstrates their capital burn rate—the net loss (R&D expenses) per scientist.
%20Chart%20Sutro%20Biopharma%20Inc.%20(STRO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Sutro-Biopharma-Inc.-STRO&v=1772588511287 "Company Profit Per Employee (in thousands of dollars) Chart Sutro Biopharma Inc. (STRO)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Sutro Biopharma is a clinical-stage biotech company developing a new generation of cancer drugs. As with other R&D firms, this timeline is a goal for the future. Currently, all value is concentrated in their scientific platform. A successful drug will allow them to generate profits above the industry average.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772588511319 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Sutro Biopharma (STRO) is an oncology company using a unique platform for creating antibodies and cytokines. They have no approved products. This chart shows the economics of their R&D. The company is in the clinical stage, and each scientist employed is an investment leading to negative returns.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772588511352 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Sutro Biopharma Inc. (STRO)
This chart for Sutro Biopharma, a company developing next-generation cancer drugs, shows the commercialization of its scientific platform. Revenue growth per employee depends on the clinical success of its own drugs and partnerships with major pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Sutro-Biopharma-Inc.-STRO&v=1772588511387 "Sales chart per company employee Sutro Biopharma Inc. (STRO)")
Sales per employee in the market segment - Oncology immuno-therapy
Sutro Biopharma is a biopharmaceutical company using its XpressCF+® platform to create antibody-drug conjugates (ADCs) for cancer treatment. This is R&D. This metric reflects the average revenue per employee in the segment. It allows us to assess how productive their R&D platform is in generating new drug candidates compared to other biotech companies.
Sales per employee for the market as a whole
Sutro Biopharma (STRO) is a clinical-stage biopharmaceutical company developing oncology drugs using its unique protein synthesis platform. Currently, its staff consists primarily of scientists. This metric is pending for STRO and will only increase if clinical trials are successful and partner fees are received.
Short shares by company, segment and market as a whole
Shares shorted by company Sutro Biopharma Inc. (STRO)
Sutro Biopharma develops oncology drugs using its complex antibody platform. The company has experienced clinical trial failures. This graph reflects investor bets that its lead candidates will fail to demonstrate safety or efficacy, and that its technology platform will prove untenable.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Sutro-Biopharma-Inc.-STRO&v=1772588511472 "Short Shares Chart for the Company Sutro Biopharma Inc. (STRO)")
Shares shorted by market segment - Oncology immuno-therapy
Sutro Biopharma (STRO) is an oncology company with a platform for developing precisely designed antibody-drug conjugates (ADCs). This chart shows the overall short position in the highly competitive ADC therapeutics sector. It reflects market skepticism about whether their platform can produce more effective drugs than their competitors.
Shares shorted by the overall market
Sutro Biopharma is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing STRO will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Sutro Biopharma Inc. (STRO)
This chart shows the market's confidence in Sutro Biopharma's platform. The company uses a unique technology (XpressCF+) to create advanced oncology drugs (ADCs). Positive data on their key drugs or a new partnership with Big Pharma triggers an "overheated" (above 70) market. Any concerns about toxicity or clinical failure lead to an "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Sutro-Biopharma-Inc.-STRO&v=1772588511525 "RSI 14 indicator chart for the company's stock Sutro Biopharma Inc. (STRO)")
RSI 14 Market Segment - Oncology immuno-therapy
Sutro (STRO) is a "biotech" company that engineers antibodies. Their platform (XpressCF+) enables the rapid creation of new "smart bombs" (ADCs) and immune stimulants to attack cancer. The "Oncology" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the entire segment. It's vital to understand: is STRO's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Sutro Biopharma (STRO) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast STRO (Sutro Biopharma Inc.)
Sutro Biopharma is a biotech company using its unique cell-free XpressCF platform to develop next-generation targeted therapies (ADCs) against cancer. This chart shows the speculative average price target from analysts, which is based entirely on their assessment of this innovative R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-STRO-Sutro-Biopharma-Inc.&v=1772588511693 "A chart showing analyst consensus forecasts for the expected stock price. STRO (Sutro Biopharma Inc.)")
The difference between the consensus estimate and the actual stock price STRO (Sutro Biopharma Inc.)
Sutro Biopharma (STRO) is a biotech company whose unique platform (XpressCF) enables the development of next-generation immunotherapies (ADCs) for cancer treatment. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-STRO-Sutro-Biopharma-Inc.&v=1772588511759 "A chart showing the difference between the consensus forecast and the actual stock price. STRO (Sutro Biopharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Sutro Biopharma (STRO) is a biotech company developing a new generation of antibody-drug conjugates (ADCs) for oncology using its cell-free platform, XpressCF. This chart shows general expectations for the immunotherapy sector, reflecting experts' confidence in this innovative R&D platform.
Analysts' consensus forecast for the overall market share price
Sutro Biopharma is a biotech company developing a platform for creating antibody-drug conjugates (ADCs)—"smart bombs" for cancer treatment. This chart shows overall risk appetite. For Sutro, a clinical-stage company in the hot ADC sector, overall market optimism is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Sutro Biopharma Inc.
Sutro Biopharma is a biotech company with a unique facility. They use a cell-free system (XpressCF) to produce complex proteins (antibodies), which they claim is faster and more accurate than traditional cell-based methods. This graph is a clear indicator of their confidence in their platform. It reflects their R&D progress and their partnerships (BMS, Merck) that validate their technology.
AKIMA Market Segment Index - Oncology immuno-therapy
Sutro Biopharma (STRO) is a biotech company developing next-generation oncology therapeutics, including antibody-drug conjugates (ADCs) and cytokines, using its cell-free platform. The chart shows the average index for the segment, allowing one to assess how Sutro's market expectations and risks compare to the overall immuno-oncology sector.
The AKIM Index for the overall market
Sutro Biopharma is a biotech company that created the XpressCF platform for the production of precision protein drugs (ADCs) for cancer. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this technology platform, with its own pipeline and partnerships, compares to overall economic trends.
